Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TACR2 | P21452 | 3/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24168933 | 1.00 | LMNA (0.41) | LMNABCHEACHEALDH1A1TACR2 | |
| SCHEMBL14817052 | 1.00 | LMNA (0.41) | LMNABCHEACHEALDH1A1TACR2 | |
| SCHEMBL23278051 | 0.83 | LMNA (0.42) | LMNABCHEACHEALDH1A1TACR2 | |
| SCHEMBL13667503 | 0.83 | IDO1 (0.31) | BCHEALDH1A1TACR2IDO1 | |
| SCHEMBL12310817 | 0.81 | CTSV (0.39) | ALDH1A1CTSVCTSLCTSBCTSS | |
| SCHEMBL18815488 | 0.78 | LMNA (0.42) | LMNABCHEACHETACR2NT5E | |
| SCHEMBL30284435 | 0.78 | LMNA (0.42) | LMNABCHEACHETACR2NT5E | |
| SCHEMBL18797789 | 0.78 | LMNA (0.42) | LMNABCHEACHEALDH1A1TACR2 | |
| SCHEMBL30901679 | 0.78 | LMNA (0.42) | LMNABCHEACHETACR2NT5E | |
| SCHEMBL18816735 | 0.78 | LMNA (0.42) | LMNABCHEACHEALDH1A1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024227159-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20220185832-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-16 | — | — | US | disclosed |
| US-20220185832-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-16 | — | — | US | disclosed |
| US-20210403497-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1`-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2020210938-A1 | QUINAZOLINE DERIVATIVES AS CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009132123-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132135-A1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-7560434-B2 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1893625-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | Biocryst Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2007002191-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403497-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1`-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, TYMS | LMNA 972/4885BCHE 3757/4885ACHE 4230/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | LMNA 1314/4885BCHE 3791/4885ACHE 4637/4885 |
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | LMNA 967/4885BCHE 3851/4885ACHE 4401/4885 |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, NSUN3, POLR2H | LMNA 3718/4885BCHE 1552/4885ACHE 4338/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | LMNA 3262/4885BCHE 3342/4885ACHE 4231/4885 |
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | LMNA 967/4885BCHE 3851/4885ACHE 4401/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | LMNA 4253/4885BCHE 1138/4885ACHE 1893/4885 |
| US-20090317361-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | CDA, PNP, MTAP | LMNA 2194/4885BCHE 2389/4885ACHE 3966/4885 |
| US-20220185832-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | LMNA 2492/4885BCHE 1824/4885ACHE 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.